Norsesquiterpenoids as well as preparation method and application thereof

By isolating and purifying sesquiterpenes from agarwood and determining their mechanism of action in liver cancer cells, the problem of insufficient research on such compounds in agarwood is solved, and new drug candidates are provided that are effective for liver cancer cells.

CN118894828AInactive Publication Date: 2024-11-05INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI HAINAN BRANCH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410945191.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, few studies have been conducted on sesquiterpenes in agarwood, especially its inhibitory effect on liver cancer cells, which has limited the full play of the anti-tumor medicinal value of agarwood.

Method used

By isolating and purifying sesquiterpenes from the ethanol extract of agarwood, using multiple chromatography and chromatography techniques, combining network pharmacology to predict targets, CHRM2 is determined as the core target, and its inhibitory effect on liver cancer cells is verified.

Benefits of technology

Successfully obtain compounds with significant cytotoxic activity against hepatocellular carcinoma cells, determine their role in the PI3K-Akt signaling pathway, provide potential anti-hepatocellular drug molecules, and verify their reliability and absorption through molecular docking and pharmacokinetics .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894828A_ABST
    Figure CN118894828A_ABST
Patent Text Reader

Abstract

The invention provides a norsesquiterpenoid compound as well as a preparation method and application thereof, the structural formula of the norsesquiterpenoid compound is # imgabs0, and the norsesquiterpenoid compound is obtained by taking an agilawood ethanol extract as a raw material through multiple separation and purification means such as silica gel column chromatography, thin-layer chromatography and high performance liquid chromatography. The norsesquiterpenoids obtained by the invention have obvious cytotoxic activity on a cancer cell line SMMC-7721, and can be used for preparing anti-liver cancer drugs. A disease target of the norsesquiterpenoids is predicted by utilizing a network pharmacology technology, and CHRM2 (also known as receptor M2) is determined to be a core action target of the norsesquiterpenoids participating in a PI3K-Akt signal channel through molecular dynamics calculation, so that the growth and reproduction of cancer cells can be intervened.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a norsesquiterpenoid compound and a preparation method and application thereof. Background Art

[0002] Agarwood is the resin-containing wood of the tree species Aquilaria or Gyrinops of the Thymelaeaceae family. Agarwood is a traditional precious spice and medicinal material in China, Japan, India and other Southeast Asian and Middle Eastern countries. It has high medicinal value and a long history of medicinal use. From the perspective of the herbal medicines of various dynasties, the sources of medicinal agarwood include imported agarwood and domestic agarwood. Domestic agarwood refers to the agarwood produced by Aquilaria sinensis (Lour.) Gilg, which is also the only source of agarwood medicinal materials specified in the Chinese Pharmacopoeia after the revision of the 1963 edition. Domestic agarwood mainly comes from Guangdong, Hainan and other places. It has the effects of promoting qi and relieving pain, warming the middle and stopping vomiting, and relieving asthma. It is often used for chest and abdominal distension and pain, stomach cold vomiting and hiccups, and kidney deficiency and qi reversal and asthma. "New Compendium of Materia Medica" says: "Agarwood warms the kidney and clears the heart. Using coptis chinensis and cinnamon to connect the heart and kidney is not as convenient as using agarwood. It is a medicine with two uses."

[0003] Agarwood has attracted extensive attention from scholars at home and abroad due to its significant role in clinical medicine. Researchers have found that agarwood contains a variety of chemical components with different structures. Previous chemical studies on agarwood have shown that sesquiterpenoids and 2-(2-phenylethyl) chromone compounds are the main chemical components in agarwood. These compounds have a variety of biological properties, such as anti-cancer, anti-inflammatory, antioxidant, antibacterial, antifungal, anti-diabetic and other pharmacological activities. At present, the relevant research on agarwood is mainly based on these two major types of component compounds, and there is no report on the research on the sesquiterpenoid compounds in the present invention and their excellent inhibitory effect on liver cancer cells. Summary of the invention

[0004] In view of this, the present invention proposes a sesquiterpenoid compound and a preparation method and application thereof, the purpose of which is to separate and study agarwood extracts, combine them with effective extraction processes, in order to discover compounds with good biological activity therefrom, and provide an important technical basis for giving full play to the anti-tumor medicinal value of agarwood.

[0005] The technical solution of the present invention is achieved in this way:

[0006] A sesquiterpenoid compound, the structural formula of the compound is:

[0007] The present invention also provides a method for preparing a norsesquiterpenoid compound. The norsesquiterpenoid compound is separated and extracted from an ethanol extract of agarwood.

[0008] Furthermore, the separation and extraction of the norosequiterpenoid compound from the ethanol extract of agarwood specifically comprises the following steps:

[0009] S1. Extract the air-dried agarwood powder with ethanol at room temperature, rotary evaporate under vacuum to obtain a crude extract, redissolve it with water, suspend the water-soluble residue in water, perform a first extraction with petroleum ether, perform a second extraction with dichloromethane, and perform a third extraction with ethyl acetate to obtain an ethyl acetate extract;

[0010] S2. The ethyl acetate extract is subjected to column chromatography, and dichloromethane-methanol, 4-methylanisole-dichloromethane and methanol-water are used as eluents for gradient elution, and the mixture is separated and purified to obtain noresquiterpenoid compounds.

[0011] Furthermore, S2 is specifically as follows: (1) subjecting the ethyl acetate extract of step S1 to D101 macroporous adsorption resin column chromatography, eluting with dichloromethane-methanol and 4-methylanisole-dichloromethane in a volume ratio of 100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100, to obtain 7 sub-fractions Fr.E1-Fr.E7, wherein fraction Fr.E1 is obtained under the condition of 4-methylanisole-dichloromethane in a volume ratio of 80:20; 2) Fraction Fr.E1 was subjected to CC analysis on a silica gel column using dichloromethane-methanol and 4-methylanisole-dichloromethane in a volume ratio of 100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, and 0:100 as eluents to obtain five sub-fractions (Fr.E1.1-Fr.E1.5), of which fraction Fr.E1.3 was obtained under the condition of dichloromethane-methanol in a volume ratio of 30:70; (3) Fraction Fr.E1.3 was subjected to Sephadex chromatography. LH-20 chromatographic column was used for separation with methanol to obtain 8 sub-fractions Fr.1.3A-Fr.1.3H, among which fraction Fr.1.3D was obtained under the condition of methanol-water with a volume ratio of 60:40; (4) fraction Fr.1.3D was further purified by LC using methanol-water with a volume ratio of 3:2 to obtain sesquiterpenoid compounds.

[0012] The present invention also provides an application of a norsesquiterpenoid compound in preparing a drug for treating liver cancer.

[0013] Furthermore, the liver cancer cell line is SMMC-7721.

[0014] Furthermore, the drug for treating liver cancer uses the receptor CHRM2 as its target.

[0015] The present invention also provides a pharmaceutical composition, comprising the above-mentioned norsesquiterpenoid compound and a pharmaceutically acceptable carrier.

[0016] Furthermore, the pharmaceutically acceptable carrier is one or more selected from fillers, diluents, solvents, sweeteners, surfactants, odorants, flavoring agents and lubricants.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] (1) The present invention proposes a sesquiterpenoid compound, which is prepared from agarwood ethanol extract by silica gel column chromatography, thin layer chromatography, high performance liquid chromatography and other separation and purification methods to obtain a sesquiterpenoid compound. The anti-tumor cell activity test results show that the compound obtained by the present invention has significant cytotoxic activity against the cancer cell line SMMC-7721, and can be used to prepare a drug for treating liver cancer.

[0019] (2) The present invention uses network pharmacology technology to predict the disease targets of the norepinephrine compound. By confirming the action pathway and core targets, it is determined that CHRM2 (also known as receptor M2) can participate in the PI3K-Akt signaling pathway and become the core target of the norepinephrine compound, thereby intervening in the growth and reproduction of cancer cells. Based on cell experiments, with the help of supercomputers, all experiments are accurate to within 2 microseconds. The experimental results verify the reliability of molecular docking and accurately calculate the pharmacokinetics of the norepinephrine compound, further confirming that the norepinephrine compound has an inhibitory effect on liver cancer cells and can be used as a potential drug molecule with good human absorption. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the structure of the norsesquiterpenoid compound of the present invention.

[0021] Figure 2 The sesquiterpenoid compound of the present invention 1 H- 1 H COSY, NOSEY and key HMBC correlations.

[0022] Figure 3 The PPI network diagram of the sesquiterpenoid compounds of the present invention is constructed.

[0023] Figure 4 This is the mechanism of action of CHRM2 in the PI3K-Akt signaling pathway.

[0024] Figure 5 The crystal structure of the M2 receptor protein (PDB 5zkc).

[0025] Figure 6Molecular docking of two different ligands NMS and the nosecone component with the M2 receptor protein.

[0026] Figure 7 MD simulation analysis of M2 receptor protein alone and in complex with NMS or compound 1 at 2 μs time intervals. DETAILED DESCRIPTION

[0027] In order to better understand the technical content of the present invention, specific embodiments are provided below to further illustrate the present invention.

[0028] Unless otherwise specified, the experimental methods used in the embodiments of the present invention are all conventional methods.

[0029] Unless otherwise specified, the materials, reagents, etc. used in the embodiments of the present invention can be obtained from commercial sources.

[0030] Example 1 Preparation of Norsesquiterpenoids

[0031] Agarwood from Pingding Town, Guangdong Province, China, which had been in the process of forming for 18 months, was selected as the experimental material. The specimen (No.: 20170818) was stored in the Key Laboratory of Sustainable Utilization of Agarwood of the State Administration of Traditional Chinese Medicine. The extraction and separation steps of the sesquiterpenoids were as follows:

[0032] S1. Extracting air-dried agarwood powder (8.0 kg) with 75% ethanol at room temperature, combining the solvents and rotary distilling under vacuum to obtain a crude extract (950 g), redissolving it with water, and after the water-soluble residue is suspended in water, performing a first extraction with petroleum ether, a second extraction with dichloromethane, and a third extraction with ethyl acetate to obtain an ethyl acetate extract;

[0033] S2, the ethyl acetate extract (35.1 g) of step S1 was chromatographed on a D101 macroporous adsorption resin column, and eluted with dichloromethane-methanol and 4-methylanisole-dichloromethane in a volume ratio of 100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, and 0:100 as eluents to obtain 7 sub-fractions (Fr.E1-Fr.E7), wherein fraction Fr.E1 was obtained under the condition of 4-methylanisole-dichloromethane (80:20, v / v);

[0034] S3, fraction Fr.E1 (15.2 g) was analyzed by CC (chromatography) on a silica gel column using dichloromethane-methanol and 4-methylanisole-dichloromethane in a volume ratio of 100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 as eluents to obtain 5 sub-fractions (Fr.E1.1-Fr.E1.5), of which fraction Fr.E1.3 was obtained under the conditions of dichloromethane-methanol (30:70, v / v);

[0035] S4, fraction Fr.E1.3 (1.2 g) was separated from methanol by Sephadex LH-20 column to obtain 8 sub-fractions (Fr.1.3A-Fr.1.3H), of which fraction Fr.1.3C was obtained under the condition of methanol-water (70:30, v / v), and fraction Fr.1.3D was obtained under the condition of methanol-water (60:40, v / v);

[0036] S5. Fraction Fr.1.3C (219.6 mg) was further purified by LC and separated with methanol-water (7:3, v / v) to obtain compound 2 (8.4 mg), compound 5 (6.9 mg), and compound 6 (7.0 mg); fraction Fr.1.3D (108.5 mg) was further purified by LC (liquid chromatography) with methanol-water (3:2, v / v) to obtain compound 1 (8.1 mg), compound 3 (9.3 mg), and compound 4 (6.1 mg).

[0037] Example 2 Structural Identification of Norsesquiterpenoids 1-6

[0038] The chemical structure of compound 1-6 obtained in Example 1 was determined by using modern structural identification techniques such as spectroscopy, hydrogen nuclear magnetic resonance spectrum, and carbon nuclear magnetic resonance spectrum.

[0039] The 1H-NMR and 13C-NMR data of the compounds are shown in Table 1.

[0040] Table 1 Compound 1 1 H and 13 C NMR (400,100MHz) spectrum

[0041]

[0042] Compound 1 was isolated as a colorless oil. Its molecular formula was determined to be C by HR-ESIMS m / z 259.1305 [M+Na]+ 14 H 20O3 (hydrogen deficiency index is 5). The 1H NMR spectrum showed an olefin signal at δH 5.78 (1H, q, J = 1.2, H-3), two consecutive methylene signals at δH 3.06 (1H, m, H-7) and δH 2.63 (1H, m, H-8), δH 2.44 (1H, br d, J = 10.4, H-6b), δH 2.41 (2H, q, J = 7.2), δH 2.25 (1H, dd, J = 4.8, 13.2, H-6a), δH 2.16 (1H, m, H-9b), δH 2.10 (1H, m, H-10b), δH 1.94 (1H, m, H-10a) and δH 1.52 (1H, m, H-9a), and three methyl groups, δH 2.07 (3H, d, J = 1.2, H-15), δH 1.04 (3H, t, J = 7.2, H-13), δH 0.84 (3H, d, J = 7.2, H-14). 13C NMR and DEPT data showed 14 carbon atoms, including a carbonyl group at δC 209, an α, β-unsaturated ketone at δC 118.8, 169.0 and 172.0, and 10 sp 3 (2 methyl, 4 methylene, 3 methyl and 1 quaternary carbon) carbon. Based on these findings, compound 1 was speculated to be a new sesquiterpenoid compound.

[0043] Since a double bond and two carbonyl groups account for three of the five hydrogen deficient indices, the remaining two unsaturations are considered to be the two ring systems present in compound 1. These inferences were supported by the 1H-1H COSY correlations of H-5 / H-6, H-6 / H-7, H-7 / H-8, H-8 / H-9, and H-9 / H-10 ( Figure 1 ) and HMBC correlations between H-3 and C-2 / C-4 / C-5, H-6 and C-4 / C-5 / C-10, and H-10 and C-4 / C-5 / C-6. The spiro connection at C-5 is believed to satisfy the above-mentioned unsaturation and the quaternary carbon nature of C-5, which is also confirmed by the HMBC correlations of H-3 with C-4 and C-5 and the HMBC correlations of H-6 and H-10 with C-4 and C-5. The presence of the propionyl group on C-7 is confirmed by the 1H-1H COSY correlation of H-12 / H-13 and the HMBC correlations of H-6, H-7, H-8 and H-12 with C-11 and H-12 with C-7. In addition, the 1H-1H COSY correlation of H-8 / H-14 and the HMBC correlation of H-14 with C-7 and C-9, as well as the HMBC correlation of H-15 with C-3, C-4, and C-5 supported the presence of two methyl groups at C-4 and C-8, respectively. Therefore, the 2D structure of compound 1 was defined as a norosequiterpenoid with a [4.5]decane ring system.

[0044] The relative configuration of compound 1 was determined based on NOESY experiments ( Figure 2 ), Ha-6 (δH 2.25) / H-8 (δH 2.63), H-8 / Ha-10 (δH 1.94), Me-13 (δH 3.06) / Me-14 (δH 0.84) and Me-13 / Me-15 (δH 2.07) strongly suggested a 5R*, 7S*, 8R* configuration. Therefore, the structure of compound 1 was defined as (5R * ,7S * ,8R * )-4,8-dimethyl-7-propionyl-1-oxaspiro[4.5]dec-3-en-2-one ((5R*,7S*,8R*)-4,8-dimethyl-7-propionyl-1-oxaspiro[4.5]dec-3-en-2-one).

[0045] The other isolated compounds 2-6 were finally identified as baimuxinal (compound 2) (baimuxinal); 11-hydroxy-valenc-1(10)-en-2-one (compound 3) (11-hydroxy-valenc-1(10)-en-2-one); (-)-eremophila-9-en-8β,11-diol (compound 4) ((-)-eremophila-9-ene-8β,11-diol); (+)-isopetasol (compound 5) ((+)-isopentanol); 5,5'-dimethoxylariciresinol (compound 6) (5,5'-dimethoxylariciresinol).

[0046] The structural formula of compound 1-6 is as follows:

[0047]

[0048] Example 3 Antitumor activity of the norsesquiterpenoid compounds of the present invention

[0049] The antitumor activities of all isolates against human hepatoma cell line (SMMC-7721), human gastric cancer cell line (MGC-803), and human ovarian cancer cell line (OV-90) were tested by MTT assay with Cisplatin and Paclitaxel as positive controls.

[0050] Table 2 Cytotoxicity of compounds 1-6 to tested cell lines

[0051]

[0052] a All results are expressed as mean ± SD, n = 3 per group;

[0053] b Positive control.

[0054] The results showed that all tested compounds showed weak cytotoxicity against various human cancer cell lines. Among them, compound 1 had a significant inhibitory effect on the human liver cancer cell line SMMC-7721.

[0055] Example 4 Network construction and analysis of compound 1 in treating liver cancer

[0056] Experimental methods:

[0057] Two databases, GeneCards (https: / / www.genecards.org / ) and DisGeNet (https: / / www.disgenet.org / ), were used to search for liver cancer-related disease genes. The keyword "Livercarcinoma" was used to search for disease targets related to liver cancer. The search results were determined by Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (https: / / david.abcc.ncifcrf.gov / ), and the gene names were standardized by UNIPOT. To ensure the credibility of the data, high correlation values ​​(≥15.0) were used for target screening, and the results of the two databases were then mixed and reorganized into the final liver cancer disease target information.

[0058] Based on the structure of compound 1, the gene targets of compound 1 were predicted by SwissTargetPrediction (https: / / www.swisstargetprediction.ch / ) and ChEMBL (https: / / www.ebi.ac.uk / chembl / ). Repeated target screening was performed on the gene targets regulated by compound 1 and the disease targets related to liver cancer to determine the potential targets for the treatment of liver cancer. Subsequently, the collected target genes were submitted to STRING (https: / / cn.string-db.org / ) to construct a protein-protein interaction (PPI) network. The target species was set to Homo sapiens, and the threshold of the interaction score was set to 0.9 with high confidence. Independent targets were deleted and the structures of the remaining targets were adjusted. The generated PPI network was visualized in Cytoscape v3.10.0, and the DEGREE values ​​of all targets of the generated connections were calculated using the plug-in provided by Cytoscape v3.10.0.

[0059] Result analysis:

[0060] After repeated screening, a total of 5329 target genes related to liver cancer-related diseases were obtained through the relevant disease target data set. According to the structure of compound 1, 66 cross-target proteins were predicted between compound 1 and liver cancer-related diseases. A high confidence of 0.9 was selected to construct the STRING protein interaction background network, which includes 66 interaction nodes and 76 edges, with an average node degree of 2.34 and an average clustering distribution coefficient of 0.422. Among them, CHRM2 and CHRM1 are interconnected to form an interactive system (such as Figure 3 shown).

[0061] CHRM2 is also named M2 receptor. Acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, decomposition of creatine phosphate, and regulation of potassium channels through the action of G proteins. The main transduction effect is to inhibit adenylate cyclase signaling, promote the activity of phospholipase C, lead to the release of inositol triphosphate (IP3) and then trigger the release of calcium ions into the cytoplasm. As the core target of the PI3K-Akt signaling pathway, the M2 receptor is involved in the regulation of the entire pathway. The mechanism of action of CHRM2 in the PI3K-Akt signaling pathway is as follows: Figure 4 shown.

[0062] As the final target of the chemokine signaling pathway, the M2 receptor is the final destination of chemokines, hormones, and neurotransmitters. Since upstream genes activate PI3K, PI3K will produce a large amount of PIP3 locally and transiently after activation, thus affecting the cell. However, its activity is strictly regulated to inhibit the transient and local catalytic PIP3 production. Two major negative feedback-mediated pathways have been identified: components of the downstream pathway and the activation of several phospholipid phosphatases. Among them, AKT is the most widely studied PI3K downstream effector, which regulates cell growth, metabolism, survival, and proliferation. Therefore, CHRM2 can be used as the core target of compound 1 to directly control the growth of liver cancer cells by directly interfering with the activation of PI3K.

[0063] Example 5 Structural analysis of the NMS binding domain of the M2 receptor protein

[0064] Experimental methods:

[0065] The three-dimensional (3D) structural analysis, molecular docking and molecular dynamics (MD) simulations of the N-methyl bromide (NMS) binding structure of the M2 receptor protein were performed using PyMol, Schrodinger and GROMACS2021.1 software packages.

[0066] The crystal structure of the M2 receptor protein in complex with the non-selective antagonist NMS was retrieved from the PDB with PDB ID 5zkc. The structural features of the NMS binding site were evaluated using the PyMol molecular visualization software. In addition, the molecular electrostatic potential map (MEP) of the M2 receptor protein was generated using the APBS plug-in in the PyMol software package.

[0067] Result analysis:

[0068] The structure of the M2 receptor protein was obtained from the PDB with PDB ID 5zkc and analyzed using the PyMol program. Figure 5 As shown, Figure 5 (A) is the overall crystal structure of the M2 receptor protein bound to the ligand NMS, the protein is shown in cartoon form (gray) and transparent surface, and the ligand NMS is shown as a stick structure; Figure 5 (B) is a partial crystal structure showing the molecular interactions between the M2 receptor protein and the NMS ligand. The ligand NMS is shown as a stick structure, colored by elements (carbon atoms in green, oxygen atoms in red, and nitrogen atoms in blue). The protein residues within 4 angstroms of the ligand NMS are shown as lines (orange), the oxygen atoms of water are shown as small spheres (red), and the hydrogen bonds between the ligand and the protein or between the ligand and water are shown as dashed lines (yellow). Figure 5 (C) Same as (B), but ligand NMS is colored by B factor, with blue to white corresponding to B factors of 25 to 35; Figure 5 (D) The binding pocket and solvent exposure of the ligand NMS are shown by displaying the protein as a gray surface and the ligand as a stick structure, colored by B factors (blue to white); Figure 5 (E) is the molecular electrostatic potential surface map (MEP) of the M2 receptor protein-NMS complex, with the maximum positive potential (+5 kcal / mol) and negative potential (-5 kcal / mol) represented in blue and red, respectively. The ligand NMS is shown as a stick structure and is colored by element.

[0069] in Figure 5 (A) shows the crystal structure of the M2 receptor protein bound to the non-selective antagonist NMS at a resolution of 2.30 Å, obtained by X-ray diffraction analysis. Figure 5(B) Illustrate the complex interaction between the ligand NMS and the M2 receptor protein, showing potential hydrogen bonds with four protein residues, one of which is mediated by water, anchoring the ligand within the binding pocket. Specifically, two hydrogen bonds are formed between the -COCH2(Ph)CH2OH fragment of NMS and residue Asn404 of the M2 receptor protein, with O…O distances of 2.4 Å and 3.4 Å, respectively. Another hydrogen bond is formed between the same part of NMS and Thr187 of the protein, mediated by a water molecule. In addition, a hydrogen bond is also formed between the COC three-membered ring of NMS and Ser107 of the M2 receptor protein, with an O…O distance of 3.2 Å.

[0070] In addition to hydrogen bonding to specific atoms of the NMS, the mobility of the ligand is also limited by steric hindrance from adjacent protein residues. Figure 5 In (C), the ligand NMS is colored by B-factor. Regions with smaller B-factors (blue) indicate greater rigidity, such as where the NMS is deep within the binding pocket ( Figure 5 (D)), while regions with larger B factors (white) indicate greater flexibility, such as the atoms of the benzene ring at the entrance of the binding pocket that are exposed to the solvent. The molecular electrostatic potential (MEP) map of the M2 receptor protein was generated using the APBS plugin in PyMol ( Figure 5 (E)). The entrance of the binding pocket is roughly located in the neutral region, neither positively nor negatively charged. However, the binding site located inside the protein shows a strong negative potential. Considering that there is no net positive charge in NMS, this suggests that the NMS ligand is partially positively charged. This conclusion is consistent with Figure 5 This is consistent with the fact that the NMS shown in B acts as a hydrogen bond acceptor (accepts protons, donates lone pairs of electrons, and is partially positively charged).

[0071] Example 6 Molecular docking with the crystal structure of M2 receptor protein

[0072] Experimental methods:

[0073] use The crystal structure of the M2 receptor protein (PDB ID5zkc) was molecularly docked using the standard procedure of the Maestro software. First, the crystal structure of the M2 receptor protein was preprocessed using the Protein Preparation module, including bond order assignment, hydrogen bond addition, and deletion of unwanted water molecules. Subsequently, the Receptor GridGeneration module was used to define the specific binding sites in the molecular docking process, and the coordinates of the NMS ligand from the M2 receptor-NMS complex (PDB ID5zkc) were used as the center of the grid box in the molecular docking. In addition, both the NMS ligand and compound 1 were optimized using the OPLS3e force field using the LigPre module. Finally, the M2 receptor protein was molecularly docked with the NMS ligand and compound 1 with extra precision (XP) using the Ligand Docking module, and the resulting XP Glide docking score (representing the binding free energy) was reported in kcal / mol.

[0074] Result analysis:

[0075] like Figure 6 As shown, Figure 6 (A) is an overlay of the crystal structure of the M2 receptor protein-NMS complex (PDB ID 5zkc, green) and the NMS-M2 receptor protein molecular docking result (brown), showing both the global structure and the enlarged view of the binding site; Figure 6 (B) is the molecular docking result of the nosecone component of the present invention and the M2 receptor protein, and the display mode is the same as Figure 5 (B) The same. Figure 6 (C) Molecular electrostatic potential (MEP) of the M2 receptor protein-deoxyterpenoid component complex, represented by the same method as Figure 5 (E)Same.

[0076] use The software performed additional accurate (XP) docking simulations of the NMS ligand on the M2 receptor protein, which produced a conformation similar to the crystallographic structure (PDB ID 5zkc), as shown in Figure 6 As shown in (A), the docking score is -10.0 kcal / mol. On the other hand, the docking results of compound 1 on M2 receptor protein use the same binding site as NMS, such as Figure 6 As shown in (B), the docking score is -8.5 kcal / mol. Although this score is weaker than the binding affinity between NMS and M2 receptor protein, it still indicates that there is a relatively strong binding affinity between compound 1 and M2 receptor protein.

[0077] like Figure 6As shown in (B), there are two potential hydrogen bonds between compound 1 and the M2 receptor protein. One hydrogen bond is formed between the five-membered ring oxygen atom of compound 1 and Ser107 of the protein, with an O…O distance of It is noteworthy that Ser107 of the M2 receptor protein is also involved in hydrogen bonding with NMS, e.g. Figure 5 (B) as described. In addition, another potential hydrogen bond is established between a carbonyl oxygen atom of compound 1 and the backbone carbonyl oxygen atom of Cys429 of the M2 receptor protein, mediated by two water molecules. Compared with the M2 receptor-NMS complex, there are fewer potential hydrogen bonds stabilizing the M2 receptor-compound 1 (2 hydrogen bonds vs. 4 hydrogen bonds), which is consistent with the observed higher docking score (lower binding free energy) of the M2 receptor-compound 1.

[0078] The molecular electrostatic potential (MEP) surface diagram of M2 receptor protein-compound 1 is shown in Figure 6 (C) shows similarities to the MEP of the M2 receptor protein-NMS complex ( Figure 5 (E)). This observation can be reasonably explained because compound 1 acts as a hydrogen bond acceptor when interacting with the M2 receptor protein, similar to the interaction mode between NMS and the M2 receptor protein.

[0079] Example 7 ADMET study of compound 1

[0080] Experimental methods: The QikProp module of Schrodinger software was used to predict the ADMET properties of compound 1. Different properties were calculated by QikProp, including molecular weight (MW), octanol / water partition coefficient (QPlogPo / w), number of hydrogen bond donors (H-donor), number of hydrogen bond acceptors (H-acceptor), oral absorption rate of the molecule (Human Oral Absorption), water solubility (QPlogS), skin permeability (QPlogKp), human serum albumin binding (QPlogKhsa), polar surface area (PSA) and solvent accessible surface area (SASA).

[0081] Result analysis:

[0082] The QikProp module of the program was used to predict the ADMET properties of compound 1, as shown in Table 3. Table 3 lists the values ​​of these properties of compound 1 of the present invention and those recommended by the Lipinski rule.

[0083] Table 3-1 ADMET prediction of compound 1 using Schrodinger method

[0084]

[0085] Table 3-2 ADMET prediction of compound 1 using Schrodinger (continued)

[0086]

[0087] The results showed that all predicted parameters were within the recommended pharmacokinetic property range and compound 1 had the potential to be a drug candidate.

[0088] Example 8 Molecular dynamics simulation of M2 receptor protein alone, M2 receptor protein-NMS and M2 receptor protein-compound 1

[0089] Experimental methods: Molecular dynamics (MD) simulations of 2 μs were performed on three different molecular systems using the GROMACS2021.1 software package: i) M2 receptor protein NMS binding domain, ii) M2 receptor protein NMS binding domain in complex with ligand NMS, iii) M2 receptor protein NMS binding domain in complex with compound 1. The purpose was to demonstrate their structural and energetic stability within a 2 μs time period.

[0090] The CHARMM-GUI server was accessed through the web page and the system was prepared in the same way. The protein or protein-ligand complex was located in a cube with a side length of 173 angstroms and immersed in a hydrated palmitoyl-oleoyl-phosphatidylcholine (POPC) lipid bilayer. TIP3 water molecules were added to fill the simulation box, and the system had a total of about 500,000 atoms under periodic boundary conditions. To maintain physiological conditions, sodium (Na) and chloride (Cl) ions were introduced to achieve a salinity of 150 mM and a neutral overall charge.

[0091] The protein, ligand, and TIP3P water were parameterized using the CHARMM36m force field. An initial energy minimization step was performed using the steepest descent algorithm for up to 5000 steps, followed by heating to 310 K and two equilibration steps. The first equilibration stage maintained the system at 310 K for 750 picoseconds (ps) at constant volume (NVT) conditions, gradually releasing from high positional constraints to no positional constraints. The second equilibration step was then performed with an additional 1 nanosecond (ns) constant pressure and constant temperature (NPT) equilibration at 1 atmosphere (atm) and 310 K.

[0092] Subsequently, the equilibrated system was subjected to a 2 μs targeted MD simulation in the NPT ensemble at 310 K and 1 atm, with the Berendsen algorithm controlling temperature and pressure and using a semi-isotropic pressure coupling algorithm. The simulation time step was set to 2.5 femtoseconds (fs), and the cutoff distance for van der Waals (vdW) and short-range electrostatic interactions was set to 12 Å. The long-range electrostatic interactions were handled using the k-space Gaussian partitioning Ewald method, and the chemical bond constraints were maintained using the M-SHAKE algorithm.

[0093] The trajectories obtained from the simulations were analyzed using the GROMACS2021.1 software package and VMD software.

[0094] Result analysis:

[0095] like Figure 7 As shown, Figure 7 (A) is the root mean square deviation diagram of the protein backbone when the M2 receptor protein acts alone (black) and in complex with NMS (red) or compound 1 (blue); Figure 7 (B) The total potential energy diagram of the entire system of the M2 receptor protein alone system (black) and the protein-ligand complex system with ligands being NMS (red) or compound 1 (blue).

[0096] The present invention performed MD simulation on three different molecular systems: i) M2 receptor protein NMS binding domain, ii) a complex of M2 receptor protein NMS binding domain and ligand NMS, and iii) a complex of M2 receptor protein NMS binding domain and compound 1.

[0097] Systems i) and ii) were used as controls, while system iii) was the target system in the MD simulations. The stability of these systems was evaluated by analyzing the trajectories obtained from the MD simulations. It was found that both the ligand NMS and compound 1 were always bound to the M2 receptor protein and located within the specified binding pocket throughout the 2 microsecond MD simulation. No dissociation of the protein-ligand complex was observed, indicating that there was a stable binding interaction between NMS and compound 1 and the M2 receptor protein within the simulation time frame. This observation is consistent with the results based on the crystal structure. Figure 5 The structural features of the binding pocket are consistent with those shown in , where the binding pocket is deeply embedded in the protein with its narrow entrance exposed to the solvent.

[0098] Furthermore, all complexes exhibited favorable structural stability compared to the M2 receptor protein alone, as reflected in the root mean square deviation (RMSD) analysis of the protein backbone atoms. Figure 7In (A), the RMSD curves of each system reached a plateau after about 150 ns, indicating that equilibrium was reached. Upon closer inspection of the equilibrium phase of the trajectory, a significant RMSD change was observed for the protein alone system between about 570 ns and 750 ns, from about 2.7 Å to 4.3 Å, indicating that a conformational change had occurred. This conformational change originated from a region of the protein loop that was exposed to the solvent and was not in the binding site. In contrast, neither the “protein + NMS” nor the “protein + compound 1” systems exhibited this RMSD change, indicating that the binding of NMS and compound 1 stabilized the M2 receptor protein. In addition, the RMSD of the “protein + compound 1” system was slightly higher than that of the “protein + NMS” system, indicating that the binding affinity of the M2 receptor-compound 1 complex may be lower than that of the M2 receptor-NMS complex.

[0099] Figure 7 (B) shows the total potential energy curves of the entire system (including protein, ligand, lipid bilayer, and water) over a 2 μs time period. Notably, these potential energy curves exhibit small fluctuations, indicating that all systems have reached equilibrium. It is noteworthy that the unbound form of the M2 receptor protein has a higher potential energy than the bound form, which may indicate that ligand binding has a stabilizing effect, whether it is NMS or compound 1. In addition, the potential energy of the "protein + NMS" system is lower than that of the "protein + compound 1" system, indicating that the binding affinity of NMS to the M2 receptor protein may be higher than that of compound 1, which is consistent with the results of molecular docking.

[0100] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A norsesquiterpenoid compound, characterized in that: The structural formula of the compound is:

2. The method for preparing a norosequiterpenoid compound according to claim 1, characterized in that: The norosequiterpenoid compound is separated and extracted from the ethanol extract of agarwood.

3. The method for preparing a norosequiterpenoid compound according to claim 2, characterized in that: The separation and extraction of the nosecone compounds from the ethanol extract of agarwood specifically comprises the following steps: S1. Extract the air-dried agarwood powder with ethanol at room temperature, rotary evaporate under vacuum to obtain a crude extract, redissolve it with water, suspend the water-soluble residue in water, perform a first extraction with petroleum ether, perform a second extraction with dichloromethane, and perform a third extraction with ethyl acetate to obtain an ethyl acetate extract; S2. The ethyl acetate extract is subjected to column chromatography, and dichloromethane-methanol, 4-methylanisole-dichloromethane and methanol-water are used as eluents for gradient elution, and the mixture is separated and purified to obtain noresquiterpenoid compounds.

4. The method for preparing a norosequiterpenoid compound according to claim 3, characterized in that: The S2 is specifically as follows: (1) subjecting the ethyl acetate extract of step S1 to D101 macroporous adsorption resin column chromatography, eluting with dichloromethane-methanol and 4-methylanisole-dichloromethane in a volume ratio of 100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0::100, to obtain 7 sub-fractions Fr.E1-Fr.E7, wherein fraction Fr.E1 is obtained under the condition of 4-methylanisole-dichloromethane in a volume ratio of 80:20; (2 ) Fraction Fr.E1 was subjected to CC analysis on a silica gel column using dichloromethane-methanol and 4-methylanisole-dichloromethane in a volume ratio of 100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, and 0:100 as eluents to obtain five sub-fractions Fr.E1.1-Fr.E1.5, of which fraction Fr.E1.3 was obtained under the condition of dichloromethane-methanol in a volume ratio of 30:70; (3) Fraction Fr.E1.3 was subjected to Sephadex chromatography. LH-20 chromatographic column was used for separation with methanol to obtain 8 sub-fractions Fr.1.3A-Fr.1.3H, among which fraction Fr.1.3D was obtained under the condition of methanol-water with a volume ratio of 60:40; (4) fraction Fr.1.3D was further purified by LC with methanol-water with a volume ratio of 3:2 to obtain sesquiterpenoid compounds.

5. Use of the norosequiterpenoid compound according to claim 1 in the preparation of a drug for treating liver cancer.

6. The use according to claim 5, characterized in that: The liver cancer cell line is SMMC-7721.

7. The use according to claim 5, characterized in that: The drug for treating liver cancer takes the receptor CHRM2 as its target.

8. A pharmaceutical composition, characterized in that The invention comprises the norsesquiterpenoid compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition according to claim 8, characterized in that: The pharmaceutically acceptable carrier is one or more selected from fillers, diluents, solvents, sweeteners, surfactants, odorants, flavoring agents and lubricants.

Citation Information

Patent Citations

  • Medicament for treating cancer

    CN104606176A

  • Preparation method of chiral gamma-butyrolactone compounds and derivatives thereof and application thereof

    CN111233795A

  • Production of 4-hydroxy-2(5H)-furanone derivative

    JP1987164677A